Anti-NMDA Receptor Encephalitis clinical trials at UCSF
1 research study open to eligible people
Anti-NMDA receptor encephalitis is a disease where the body's immune system attacks the brain. UCSF is studying a drug called Satralizumab to see if it helps people with this condition. The trial looks at how safe and effective the drug is for patients.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Last updated: